Drug eruption due to bosentan in a patient with systemic sclerosis

Modern Rheumatology

Volumn 16, Issue 3, 2006, Pages 188-190

  Nagai, Yayoi ^a   Yamanaka, Masayoshi ^a   Nishimura, Shigeru ^a   Nakano, Akihiko ^a   Hasegawa, Akira ^a   Ishikawa, Osamu ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Bosentan; Drug eruption; Endothelin receptor antagonist; Pulmonary arterial hypertension (PAH); Systemic sclerosis (SSc)

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ANTINUCLEAR ANTIBODY; BOSENTAN; FAMOTIDINE; FUROSEMIDE; OMEPRAZOLE; PREDNISOLONE; PRONASE; SPIRONOLACTONE;

ADULT; ANAMNESIS; ARTICLE; BIOPSY TECHNIQUE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG FEVER; DRUG REEXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; FEMALE; HEART CATHETERIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROVOCATION TEST; PULMONARY HYPERTENSION; RECURRENT DISEASE; REFLUX ESOPHAGITIS; SEROLOGY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; DRUG ERUPTIONS; EOSINOPHILIA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PREDNISOLONE; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 33745052071     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-006-0477-3     Document Type: Article

References (14)

1. MD Mayes 2003 Endothelin and endothelin receptor antagonists in systemic rheumatic disease Arthritis Rheum 48 1190-9 12746891 1:CAS:528:DC%2BD3sXkt1aksb0%3D 10.1002/art.10895
2. A Ramirez J Varga 2004 Pulmonary arterial hypertension in systemic sclerosis Treat Respir Med 3 339-52 15658881 10.2165/ 00151829-200403060-00002
3. E Hachulla JG Coghlan 2003 A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism Ann Rheum Dis 63 1009-14 10.1136/ard.2003.017673
4. RN Channick G Simommeau O Sitbon IM Robbins A Frost VF Tapson 2001 Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study Lancet 358 1119-23 11597664 1:CAS:528:DC%2BD3MXntlOrurs%3D 10.1016/ S0140-6736(01)06250-X
5. RE Girgis SC Mathai JA Krihnan FM Wigley PM Hassoun 2003 Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases J Heart Lung Transplant 24 1626-31 10.1016/j.healun.2004.12.113
6. K Yamane T Miyaushi N Suzuki C Wheeler-Jones I Olsen R Penny et al. 1994 Significance of plasmaendothelin-1 levels in patients with systemic sclerosis J Rheumatol 21 1838-44
7. ET Koh P Lee DD Gladman M Abu-Shakra 1996 Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients Br J Rheumatol 35 989-93 8883438 1:STN:280:ByiD3sjotFQ%3D 10.1093/rheumatology/35.10.989
8. AM Stupi VD Steen GR Owes et al. 1986 Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis Arthritis Rheum 29 515-24 3707629 1:STN:280:BimB3Mrjs1Y%3D
9. K Fattinger C Funk M Pantze C Weber J Reichen B Stieger et al. 2001 The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions Clin Pharmacol Ther 69 223-31 11309550 1:CAS:528:DC%2BD3MXjvVelsbo%3D 10.1067/ mcp.2001.114667
10. S Gasser M Kuhn R Speich 2003 Severe necrotizing leucocytoclastic vasculitis on a patient taking bosentan BMJ 329 43010.1136/ bmj.329.7463.430
11. M Humbert J Cabane 2003 Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan Rheumatology 42 191-3 12509640 1:CAS:528:DC%2BD3sXovFaksg%3D%3D 10.1093/rheumatology/keg050
12. MJ Snyder MR Jacobs RG Gran DS Wilkers KS Knox 2005 Resolution of severe digital ulceration during a course of bosentan therapy Ann Intern Med 142 802-23 15867420
13. M Ramos-Casals P Brito-Zeron N Nardi G Claver G Risco FD Parraga 2004 Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis Rheumatology 43 1454-6 15502001 1:STN:280:DC%2BD2crjtF2itA%3D%3D 10.1093/rheumatology/keh340
14. HJ Korn M Mayes M Matucci Cerinic M Rainisio J Pope E Hachulla et al. 2004 Digital ulcers in systemic sclerosis. Prevention by treatment with Bosentan, an oral endothelin receptor antagonist Arthritis Rheum 50 3985-93 15593188 1:CAS:528:DC%2BD2MXls1eguw%3D%3D 10.1002/art.20676